Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling
暂无分享,去创建一个
M. Rugge | L. Cascione | M. Fassan | M. Galasso | A. D. Dei Tos | S. Barollo | L. Bertazza | F. Galuppini | F. Vianello | G. Pennelli | C. Mian | N. Valeri | J. Hahne | S. Censi | M. Sbaraglia | G. Munari | I. Merante Boschin
[1] E. Kimura,et al. Targeting the Highly Expressed microRNA miR-146b with CRISPR/Cas9n Gene Editing System in Thyroid Cancer , 2021, International journal of molecular sciences.
[2] Yan Liu,et al. A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma , 2021, PloS one.
[3] M. Fassan,et al. MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives , 2021, Cells.
[4] N. Chauhan,et al. miR-205: A Potential Biomedicine for Cancer Therapy , 2020, Cells.
[5] M. Sorokin,et al. Reciprocal Dysregulation of MiR-146b and MiR-451 Contributes in Malignant Phenotype of Follicular Thyroid Tumor , 2020, International journal of molecular sciences.
[6] Wenqian Jiang,et al. Downregulation of miR-146b-5p via iodine involvement repressed papillary thyroid carcinoma cell proliferation. , 2020, Journal of molecular endocrinology.
[7] Jian Sun,et al. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma , 2019, Human Cell.
[8] Hong-Yo Kang,et al. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer , 2017, International journal of molecular sciences.
[9] A. Sapino,et al. Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma. , 2017, Endocrine-related cancer.
[10] S. Benvenga,et al. The micropapillary/hobnail variant of papillary thyroid carcinoma: A review of series described in the literature compared to a series from one southern Italy pathology institution , 2016, Reviews in Endocrine and Metabolic Disorders.
[11] M. Rugge,et al. MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma , 2016, British Journal of Cancer.
[12] M. Rugge,et al. BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience , 2016, Clinical chemistry and laboratory medicine.
[13] A. Tischler,et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. , 2016, JAMA oncology.
[14] Simion I. Chiosea,et al. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation. , 2016, Thyroid : official journal of the American Thyroid Association.
[15] A. Salajegheh,et al. Modulatory role of miR-205 in angiogenesis and progression of thyroid cancer. , 2015, Journal of molecular endocrinology.
[16] Alan Sharpe,et al. High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma. , 2015, Cancer research.
[17] Robert A. Smith,et al. The important roles of miR-205 in normal physiology, cancers and as a potential therapeutic target. , 2014, Current cancer drug targets.
[18] D. Dias-Santagata,et al. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. , 2014, Thyroid : official journal of the American Thyroid Association.
[19] Julia B. Cordero,et al. MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer , 2014, Cancer cell.
[20] C. Croce,et al. Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer , 2013, PloS one.
[21] M. Nikiforova,et al. MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma , 2011, Annals of Surgical Oncology.
[22] Kuender D Yang,et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. , 2010, Thyroid : official journal of the American Thyroid Association.
[23] R. Lloyd,et al. Papillary Thyroid Carcinoma With Prominent Hobnail Features: A New Aggressive Variant of Moderately Differentiated Papillary Carcinoma. A Clinicopathologic, Immunohistochemical, and Molecular Study of Eight Cases , 2010, The American journal of surgical pathology.
[24] Shuji Fujita,et al. Locked Nucleic Acid In situ Hybridization Analysis of miR-21 Expression during Colorectal Cancer Development , 2009, Clinical Cancer Research.
[25] C. Nucera,et al. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). , 2009, Biochimica et biophysica acta.
[26] S. Schokrpur,et al. Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.
[27] G. Goodall,et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.
[28] G. Tseng,et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. , 2008, The Journal of clinical endocrinology and metabolism.
[29] D. Baltimore,et al. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.
[30] C. Croce,et al. A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[31] V. Trovisco,et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness , 2005, Virchows Archiv.
[32] M. Gariboldi,et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer , 2004, Oncogene.
[33] M. Nikiforova,et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.
[34] C. Brown,et al. Primary malignant tumours of the thyroid: The relationship between histological classification and clinical behaviour , 1976, The British journal of surgery.
[35] J. Mejzlík,et al. MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation , 2021, In Vivo.
[36] S. Barollo,et al. The Hobnail Variant of Papillary Thyroid Carcinoma: Clinical/Molecular Characteristics of a Large Monocentric Series and Comparison with Conventional Histotypes. , 2018, Thyroid : official journal of the American Thyroid Association.
[37] M. Rugge,et al. PDCD4 expression in thyroid neoplasia , 2012, Virchows Archiv.
[38] S. Pilotti,et al. Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma , 2002, Virchows Archiv.
[39] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .